Navigation Links
Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
Date:2/5/2009

/p>

Study Background

This multicenter, open-label phase I/II study was designed to determine the recommended dose, cardiac safety and antitumor activity of nonpegylated liposomal doxorubicin, paclitaxel and trastuzumab in patients with HER-2-overexpressing locally advanced nonoperable breast cancer (LABC) or metastatic breast cancer (MBC).

Sixty-nine adult patients from Spain participated, 15 in the dose escalating part and 54 at the recommended phase II dose. Women with measurable, previously untreated, HER-2-overexpressing LABC and MBC - and a baseline left ventricular ejection fraction (LVEF) > 50 percent - received weekly trastuzumab in combination with escalating doses of weekly paclitaxel and nonpegylated liposomal doxorubicin every three weeks for six cycles. Overall response rate was defined as the total of complete response plus partial response. LVEF was monitored every 3 weeks for the first 18 weeks and every eight weeks thereafter.

Study Results

No case of symptomatic treatment-related cardiac failure was reported. A total of 12 patients (17%) developed asymptomatic minimal and reversible declines in LVEF. In eight of these patients, LVEF recovered to greater than or equal to 50% after a median time of nine weeks (range, 3-38 weeks). In the remaining patients, LVEF ranged from 44% to 49%.

The combination therapy was highly active and well-tolerated. The overall response rate, at the recommended phase II dose, was 98.1%: 29 patients achieved a complete response (53.7%) and 24 patients had a partial response (44.4%). This response rate ranks among the highest reported in HER-2-overexpressing breast cancer patients. The median time to progression was not reached in patients with locally advanced nonoperable breast cancer, while it exceeded 21 months in those with metastatic disease. The most common adverse events included alopecia (85.1%), mucosal inflammati
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
2. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
4. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
9. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
11. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... , June 21 /PRNewswire-FirstCall/ - Aeterna Zentaris ... a late-stage drug development company specialized in oncology and ... announced registered direct offering of US$12.1 million ... purchase warrants to certain institutional investors. Net proceeds from ...
... June 21, 2010 The Pharmaceutical practice,at MarketsandMarkets is pleased to announce a new report ... , ... , , ... , , ...
... in power capacity as a result of a new finding ... for one of the battery,s electrodes produced a significant increase ... it could deliver from a given weight of material, compared ... in small portable devices, and with further research might also ...
Cached Biology Technology:Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 2Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 3Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 2Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 3Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 4Using carbon nanotubes in lithium batteries can dramatically improve energy capacity 2Using carbon nanotubes in lithium batteries can dramatically improve energy capacity 3
(Date:7/9/2014)... candidate developed by researchers at the NIH,s ... and its collaborators to treat sickle cell ... BioScience business. The drug candidate, Aes-103, is ... underlying molecular mechanism of sickle cell disease. ... activities required for regulatory approval and commercialization. ...
(Date:7/9/2014)... southern Europe are less fit in terms of ... European peers. Moreover, southern adolescents are more obese ... fat than those from the centre-north of Europe. ... from an ambitious study conducted by scientists from ... in collaboration with 25 other European research groups. ...
(Date:7/9/2014)... yield big savings, if they are used in ... the Brigham and Women,s Hospital and coauthors analyzed ... savingshigh-cost patients; readmissions; triage; decompensation (when a patient,s ... a disease affects multiple organ systems. They suspect ... current costs associated with all six scenarios will ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4Adolescents from southern Europe are less fit and more obese than central-northern European peers 2The impact of big data on health care: Health Affairs' July issue 2
... CITY, MO Cells trying to keep pace with constantly ... between maintaining their genomic integrity and allowing enough genetic ... study, researchers at the Stowers Institute for Medical Research ... genomes become unstable, readily acquiring or losing whole chromosomes ...
... the genetic variance of human metabolism, researchers have identified ... with levels of circulating metabolites, i.e., small molecules that ... Many of the studied metabolites are biomarkers for cardiovascular ... provide valuable insight into the biological processes leading to ...
... the researchers to see an aspect of light that humans ... sensitive to polarized light, many reef dwelling animals are but ... studies of reef communities. Thanks to generous support provided ... team of researchers from the Ecology of Vision Laboratory in ...
Cached Biology News:That which does not kill yeast makes it stronger 2That which does not kill yeast makes it stronger 3Genetic regulation of metabolomic biomarkers - paths to cardiovascular diseases and type 2 diabetes 2Capturing an octopus-eye view of the Great Barrier Reef 2
... The mycobacteria in Complete Freund's adjuvant attract ... site which enhances the immuneresponse. For this ... for the initial injections; Incomplete Freund's adjuvant ... (preferably in saline) are typically mixed with ...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
2,4-Dinitrophenyl hapten is conjugated to Keyhole Limpet (KLH) protein through lysine....
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
Biology Products: